AAAAAA
Results: 1-25/84
Authors:
Miller, MD
Margot, NA
Hertogs, K
Larder, B
Miller, V
Citation: Md. Miller et al., Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples, NUCLEOS NUC, 20(4-7), 2001, pp. 1025-1028
Authors:
Miller, V
Citation: V. Miller, Resistance to protease inhibitors, J ACQ IMM D, 26, 2001, pp. S34-S50
Authors:
Miller, V
Larder, BA
Citation: V. Miller et Ba. Larder, Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure, ANTIVIR TH, 6, 2001, pp. 25-44
Authors:
Miller, V
Citation: V. Miller, Interpretation of resistance assay results, ANTIVIR TH, 6, 2001, pp. 1-9
Authors:
Vandamme, AM
Houyez, F
Banhegyi, D
Clotet, B
De Schrijver, G
De Smet, KAL
Hall, WW
Harrigan, R
Hellmann, N
Hertogs, K
Holtzer, C
Larder, B
Pillay, D
Race, E
Schmit, JC
Schuurman, R
Shulse, E
Sonnerborg, A
Miller, V
Citation: Am. Vandamme et al., Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up, ANTIVIR TH, 6(1), 2001, pp. 21-39
Authors:
Miller, V
Citation: V. Miller, Structured treatment interruptions in antiretroviral management of HIV-1, CURR OPIN I, 14(1), 2001, pp. 29-37
Authors:
Sagher, FA
Miller, V
Ward, IC
Citation: Fa. Sagher et al., Red cell fatty acid profile and elemental diet in childhood Crohn's disease, SAUDI MED J, 22(10), 2001, pp. 931-931
Authors:
Richardson, G
Griffiths, AM
Miller, V
Thomas, AG
Citation: G. Richardson et al., Quality of life in inflammatory bowel disease: A cross-cultural comparisonof English and Canadian children, J PED GASTR, 32(5), 2001, pp. 573-578
Authors:
Kirk, O
Mocroft, A
Pradier, C
Bruun, JN
Hemmer, R
Clotet, B
Miller, V
Viard, JP
Phillips, AN
Lundgren, JD
Citation: O. Kirk et al., Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir, AIDS, 15(8), 2001, pp. 999-1008
Authors:
Miller, V
Vandamme, AM
Loveday, C
Staszewski, S
Lundgren, J
Youle, M
Ait-Khaled, M
Boucher, C
Brun-Vezinet, F
Dedes, N
Giaquinto, C
Hertogs, K
Houyez, F
Perrin, L
Pillay, D
Schmit, JC
Schuurman, R
Lange, J
Banhegyi, D
Biondi, G
Broekhuizen, A
Bush-Donovan, C
Camacho, R
Carlier, H
Clavel, F
Clotet, B
Clumeck, N
Colebunders, R
De Clerq, K
De Jaegher, JJ
De Schrijver, G
De Smet, K
Hall, W
Harrigan, R
Hatzakis, A
Hellmann, N
Hoetelmans, R
Holtzer, C
Katlama, C
Larder, D
Loriaux, E
McCreedy, B
Mulcahy, F
Opravil, M
Phillips, A
Ruiz, N
Shulse, E
Sonnerborg, A
Soriano, V
Steel, H
Vella, S
Williams, A
Citation: V. Miller et al., Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting, AIDS, 15(3), 2001, pp. 309-320
Authors:
Mocroft, A
Phillips, AN
Miller, V
Gatell, J
van Lunzen, J
Parkin, JM
Weber, R
Roge, B
Lazzarin, A
Lundgren, JD
Citation: A. Mocroft et al., The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study, AIDS, 15(2), 2001, pp. 201-209
Authors:
Harrigan, PR
Montaner, JSG
Wegner, SA
Verbiest, W
Miller, V
Wood, R
Larder, BA
Citation: Pr. Harrigan et al., World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing, AIDS, 15(13), 2001, pp. 1671-1677
Authors:
Lepri, AC
Miller, V
Phillips, AN
Rabenau, H
Sabin, CA
Staszewski, S
Citation: Ac. Lepri et al., The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load, AIDS, 15(1), 2001, pp. 47-54
Authors:
Phillips, AN
Staszewski, S
Weber, R
Kirk, O
Francioli, P
Miller, V
Vernazza, P
Lundgren, JD
Ledergerber, B
Citation: An. Phillips et al., HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load, J AM MED A, 286(20), 2001, pp. 2560-2567
Authors:
Georgoulias, V
Scagliotti, G
Miller, V
Eckardt, J
Douillard, JY
Manegold, C
Citation: V. Georgoulias et al., Challenging the platinum combinations: Docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer, SEMIN ONCOL, 28(1), 2001, pp. 15-21
Authors:
Miller, V
Savage, M
Citation: V. Miller et M. Savage, Changes in seismic anisotropy after volcanic eruptions: Evidence from Mount Ruapehu, SCIENCE, 293(5538), 2001, pp. 2231-2233
Authors:
Miller, V
Citation: V. Miller, Currency crises., J ECON HIST, 61(2), 2001, pp. 585-586
Authors:
Miller, V
Citation: V. Miller, Insane sisters; or, The price paid for challenging a company town., J AM HIST, 87(4), 2001, pp. 1528-1529
Authors:
Kirk, O
Pedersen, C
Cozzi-Lepri, A
Antunes, F
Miller, V
Gatell, JM
Katlama, C
Lazzarin, A
Skinhoj, P
Barton, SE
Citation: O. Kirk et al., Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy, BLOOD, 98(12), 2001, pp. 3406-3412
Authors:
Miller, V
Citation: V. Miller, Special section: European guidelines - Introduction, ANTIVIR TH, 5(2), 2000, pp. 105-105
Authors:
Mocroft, A
Miller, V
Chiesi, A
Blaxhult, A
Katlama, C
Clotet, B
Barton, S
Lundgren, JD
Citation: A. Mocroft et al., Virological failure among patients on HAART from across Europe: results from the EuroSIDA study, ANTIVIR TH, 5(2), 2000, pp. 107-112
Authors:
Youle, M
Holtzer, C
Simpson, K
de Clerq, K
Miller, V
Citation: M. Youle et al., HIV-1 drug resistance testing: health outcomes issues, ANTIVIR TH, 5(2), 2000, pp. 113-115
Authors:
DeGruttola, V
Dix, L
D'Aquila, R
Holder, D
Phillips, A
Ait-Khaled, M
Baxter, J
Clevenbergh, P
Hammer, S
Harrigan, R
Katzenstein, D
Lanier, R
Miller, M
Para, M
Yerly, S
Zolopa, A
Murray, J
Patick, A
Miller, V
Castillo, S
Pedneault, L
Mellors, J
Citation: V. Degruttola et al., The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan, ANTIVIR TH, 5(1), 2000, pp. 41-48
Authors:
Miller, V
Cozzi-Lepri, A
Hertogs, K
Gute, P
Larder, B
Bloor, S
Klauke, S
Rabenau, H
Phillips, A
Staszewski, S
Citation: V. Miller et al., HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort, ANTIVIR TH, 5(1), 2000, pp. 49-55
Authors:
Regens, JL
Obenshain, KR
Gunter, JT
Miller, V
Citation: Jl. Regens et al., Modeling radiological risks to human health from contaminated soils: Comparing MEPAS, MMSOILS, and RESRAD, HUM ECOL R, 6(5), 2000, pp. 777-788